HGH Fragment 176–191

Modified GH Peptide · Targeted Lipolysis

HGH Fragment 176–191 is a stabilised analogue of the C-terminal end of Human Growth Hormone — specifically the amino acid sequence spanning positions 176 to 191. Peptigain supplies this compound as an isolated, precision-engineered fragment designed to amplify the fat-burning properties of full-length HGH while eliminating its insulin-antagonising and growth-promoting effects.

Key Research Areas:

Targeted Lipolysis — Directly activates fat-burning pathways, particularly in adipose tissue depots
No Insulin Disruption — Does not elevate blood glucose, unlike full HGH
Anti-Lipogenic — Inhibits new fat cell formation, studied for long-term body composition research
Muscle Preservation — Research suggests lean tissue is maintained even during caloric restriction

Specifications:

Type: Modified HGH C-Terminal Fragment | Sequence: AA 176–191 | Purity: ≥98% HPLC Verified | Format: Lyophilised Powder
For Research Use Only — Not for Human Administration